Analyst Research Report Snapshot

Title:

PROMETIC LIFE SCIENCES - CREATING OPPORTUNITIES IN H212

Price:

$10.00

Provider:

Edison Investment Research

Date:

10 Sep 2012

Pages:

12

Type:

AcrobatPDF

Companies referenced:

PLI.TO CELG.OQ

Available for Immediate Download
Summary:

ProMetic Life Sciences is confident of continuing a trend of increasing revenues and decreasing EBITDA losses in H212. Improved order visibility suggests FY12 revenues will be at least C$21m, with potential for further upgrades. The company has clearly defined corporate objectives for 2012 and has made solid progress so far. The investment case continues to rest on deriving greater value from its proprietary ligand (binding) enabling technologies as ProMetic moves up the value chain. New contracts (service or product related) could represent upside, as would new agreements for plasma-derived products with strategic partners (such as those recently secured with Hematech and NantPharma) or licensing deals for its novel oral small molecule drugs.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.